Nasdaq · CIK 0001377121 · PHARMACEUTICAL PREPARATIONS
Protagonist Therapeutics, Inc
PTGX chart by TradingView
PRICE HISTORY
LIVE · NASDAQPTGX chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $0.0B
- EBITDA
- $-0.2B
- FREE CASH FLOW
- $0.1B
- EPS
- $-2.05
- GROSS MARGIN
- —
- ROIC
- —
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 27 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
105.0x
+825%8.7x105.0x
⤢
P / SALES (TTM)
30.9x
-27%5.5x1354.1x
⤢
P / BOOK
10.3x
+134%1.4x11.3x
⤢
EV / EBITDA (TTM)
—
⤢
EV / REVENUE (TTM)
—
⤢
FCF YIELD (TTM)
1.50%
+7.7pp-27.77%11.01%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.2B
+2331%⤢
EBITDA (DERIVED)
$0.2B
+$0.2B⤢
NET INCOME
$0.2B
+$0.2B⤢
EPS (DILUTED)
$2.29
+$2.84⤢
REVENUE GROWTH YOY
3749.17%
+3699.8pp-100.00%3749.17%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
102.53%
-358.8pp-1621.07%6445.74%
⤢
RETURN ON CAPITAL
—
⤢
RETURN ON EQUITY (TTM)
9.85%
+44.9pp-64.85%40.75%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN—
OPERATING MARGIN74.37%
NET MARGIN76.28%
FCF MARGIN102.53%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.2B
+440%⤢
STOCK-BASED COMP
$0.0B
+1063%⤢
CAPITAL EXPENDITURE
$0.0B
-12%⤢
SHARES OUTSTANDING
0.07B
+61%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.4B
+734%⤢
TOTAL DEBT
—
⤢
DEBT / EBITDA (TTM)
—
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 125.37%INSIDERS 0.71%OTHER / RETAIL 0.00%463 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 15.21% | 9.8M | $1.43B | +0.6% |
| Farallon Capital Management LLC | 9.87% | 6.3M | $926.1M | NEW |
| UBS Group AG | 8.05% | 5.2M | $755.3M | +86.9% |
| RTW Investments LP | 7.87% | 5.1M | $738.0M | +0.0% |
| Wellington Management Group, LLP | 5.60% | 3.6M | $525.1M | +13.5% |
| Vanguard Portfolio Management LLC | 5.41% | 3.5M | $507.8M | NEW |
| State Street Corporation | 4.85% | 3.1M | $454.6M | -2.6% |
| Janus Henderson Group PLC | 4.50% | 2.9M | $421.8M | +9.1% |
| Vanguard Capital Management LLC | 4.36% | 2.8M | $409.3M | NEW |
| Johnson & Johnson | 3.81% | 2.4M | $357.3M | +0.0% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.